⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL731818 | 1.00 | — | — | |
| SCHEMBL2883958 | 1.00 | — | — | |
| SCHEMBL102678 | 0.86 | — | — | |
| SCHEMBL1183640 | 0.85 | — | — | |
| SCHEMBL1184718 | 0.85 | — | — | |
| SCHEMBL220279 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL27006569 | 0.84 | NCF1 (0.54) | — | |
| Iodide SCHEMBL6364272 | 0.84 | NCF1 (0.54) | — | |
| SCHEMBL16707755 | 0.83 | BRD4 (0.43) | — | |
| Hydrochloric Acid SCHEMBL11086419 | 0.83 | SMN1; SMN2 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260085053-A1 | BENZOFURAN DERIVATIVES AS SIK INHIBITORS AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2026-03-26 | — | — | US | disclosed |
| US-20260049071-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | BEYANG THERAPEUTICS CO LTD (CN) | 2026-02-19 | — | — | US | disclosed |
| EP-4688739-A1 | NOVEL PYRROLIDINIUM COMPOUNDS HAVING ANTAGONISTIC ACTIVITY AGAINST MUSCARINIC RECEPTORS AND USE THEREOF | eFlask Co., Ltd. (KR) | 2026-02-11 | — | — | EP | disclosed |
| US-20260022132-A1 | SPIROCYCLIC DIHYDROPYRANOPYRIMIDINE KRAS INHIBITORS | TREELINE BIOSCIENCES INC (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4570805-A1 | TRICYCLIC COMPOUNDS AND MEDICAL USE THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2025-06-18 | — | — | EP | disclosed |
| EP-4556466-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | Beyang Therapeutics Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| WO-2025038936-A1 | SPIROCYCLIC DIHYDROPYRANOPYRIMIDINE KRAS INHIBITORS | Treeline Biosciences, Inc. (US) | 2025-02-20 | — | — | WO | disclosed |
| WO-2024205157-A1 | NOVEL PYRROLIDINIUM COMPOUNDS HAVING ANTAGONISTIC ACTIVITY AGAINST MUSCARINIC RECEPTORS AND USE THEREOF | EFLASK CO., LTD. (KR) | 2024-10-03 | — | — | WO | disclosed |
| US-20240309020-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2024-09-19 | — | — | US | disclosed |
| US-20120238751-A1 | TRICYCLIC GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120238751-A1 | TRICYCLIC GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| WO-2012125746-A1 | TRICYCLIC GYRASE INHIBITORS | TRIUS THERAPEUTICS INC. (US) | 2012-09-20 | — | — | WO | disclosed |
| US-8188272-B2 | Fused heterocyclic compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-05-29 | — | — | US | disclosed |
| WO-2011163518-A1 | PYRAZOLO [1, 5 -A] PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| EP-2176250-B1 | SUBSTITUTED HETEROARYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS CH (CH) | 2011-10-26 | — | — | EP | disclosed |
| US-20100249093-A1 | Substituted Heteroarylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-09-30 | — | — | US | disclosed |
| US-20100249093-A1 | Substituted Heteroarylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-09-30 | — | — | US | disclosed |
| US-20100105676-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-29 | — | — | US | disclosed |
| WO-2009010299-A1 | SUBSTITUTED HETEROARYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2009-01-22 | — | — | WO | disclosed |